SPDL1 and neoplasm: Baseline sPD-L1 has proven to be a reliable tumor marker in metastatic breast cancer (48) and has been linked to rapid metastatic progression in metastatic ccRCC (51), as well as to the size of metastases in colorectal cancer (56).